Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.65 |
| ▸ | CDK2 | P24941 | 4/20 | 0.62 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827485 | 0.79 | CDK2 (0.61) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL8010398 | 0.79 | CDK1 (1.00) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL7999866 | 0.79 | CDK1 (1.00) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL17442999 | 0.79 | CDK1 (0.73) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL13252976 | 0.78 | CDK1 (0.81) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| Olomoucine SCHEMBL135056 | 0.77 | CDK1 (1.00) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL5827486 | 0.76 | CDK2 (0.58) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL5828515 | 0.76 | CDK2 (0.74) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL3965242 | 0.75 | CDK1 (0.66) | CDK1CDK2CCNE2CCNE1CCNA2 | |
| SCHEMBL14182620 | 0.75 | CDK1 (0.87) | CDK1CDK2CCNE2CCNE1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-12-15 | — | — | US | claimed |
| EP-3825692-B1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2024-09-04 | — | — | EP | disclosed |
| EP-3553186-B1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | INBIOMOTION SL (ES) | 2021-11-17 | — | — | EP | disclosed |
| EP-3825692-A1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | Fundació Institut de Recerca Biomèdica (IRB Barcelona) (ES) | 2021-05-26 | — | — | EP | disclosed |
| EP-3272880-B1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF METASTATIC CANCER | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2020-11-25 | — | — | EP | disclosed |
| EP-2971113-B1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2020-08-12 | — | — | EP | disclosed |
| EP-3553186-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | Inbiomotion S.L. (ES) | 2019-10-16 | — | — | EP | disclosed |
| EP-2906718-B1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS USING C-MAF | INBIOMOTION SL (ES) | 2019-05-15 | — | — | EP | disclosed |
| EP-3467124-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER METASTASIS | Fundació Institut de Recerca Biomèdica IRB (Barcelona) (ES) | 2019-04-10 | — | — | EP | disclosed |
| EP-2859120-B1 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF LUNG CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2018-11-14 | — | — | EP | disclosed |
| US-6794390-B2 | TREATING CELL PROLIFERATIVE DISORDERS SUCH AS RHEUMATOID ARTHRITIS, LUPUS, TYPE I DIABETES, MULTIPLE SCLEROSIS, CANCER, RESTENOSIS, HOST GRAFT DISEASE, GOUT, AND POLYCYSTIC KIDNEY DISEASE. | CV THERAPEUTICS, INC. | 2004-09-21 | — | — | US | disclosed |
| US-6790958-B2 | ANTIPROLIFERATIVE AGENTS; FUNGICIDES | LUM ROBERT T (US) | 2004-09-14 | — | — | US | disclosed |
| US-20020032327-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha | CV THERAPEUTICS, INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1150982-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a) | CV THERAPEUTICS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021186-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021186-A4 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2000-07-26 | — | — | EP | disclosed |
| US-5866702-A | Purine inhibitors of cyclin dependent kinase 2 | CV THERAPEUTICS, INCORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998005335-A9 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005335-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | CV THERAPEUTICS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | CDK1 2928/4885CDK2 4303/4885CCNE2 2197/4885 |
| US-20020032327-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha | CDKN1A, CCNK, CDK1 | CDK1 3/4885CDK2 4/4885CCNE2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.